| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-299 | |
| Phytochemical name or plant extracts | Euphosorophane A | |
| PMID | 29407947 | |
| Literature evidence | Eight compounds (1, 2, 4, 6, 8, 10, 11, and 15) showed promising chemoreversal abilities compared to verapamil (VRP). | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Diterpenoid | |
| Source of phytochemicals or plant Extracts | Euphorbia sororia | |
| Geographical availability | Iran, Kazakhstan, Kirgizstan, Pakistan, Tadzhikistan, Transcaucasus, Uzbekistan, Xinjiang | |
| Plant parts | Fruits | |
| Other cancers | Breast cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | >100 µM against MCF-7 | |
| Potency | The most potent compound, Euphosorophane A (1), possessed many advantages, including (1) high potency (EC50 = 92.68 ± 18.28 nM) in reversing P-gp-mediated resistance to doxorubicin (DOX), low cytotoxicity, and a high therapeutic index, (2) potency in reversing resistance to other cytotoxic agents associated with MDR, and (3) inhibition of P-gp-mediated Rhodamine123 (Rh123) efflux function in MCF-7/ADR cells. | |
| Cell line/ mice model | MCF-7/ADR | |
| Additional information | The results of the Western blot analysis indicated that the multidrug resistance (MDR) reversal induced by 1 was not due to the inhibiton of P-gp expression. Compound 1 stimulated P-gp-ATPase activity and caused the dose-dependent inhibition of DOX transport activity. | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:348311-1 | |
| Safety | NA |